gimli
PANACEABIO stock AI analysis

PANACEABIO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

PANACEA BIOTEC LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available PANACEABIO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Price
₹548.85
1W return
+1.17%
1M return
+2.32%
3M return
+60.67%
6M return
+43.32%
1Y return
+27.91%
Market cap
₹3,361.74 cr
PE
-626.02
PB
4.06
ROE
-0.65%
ROCE
-0.16%
RSI
55.59
Turnover
₹6.09 cr

Why it can matter in screens

Quick Answers

What is the latest PANACEABIO stock price?

The latest stored price for PANACEABIO is Rs 548.85 as of 2026-07-20.

Is PANACEABIO above its 50DMA and 200DMA?

PANACEABIO is above 50DMA, above 200DMA. The latest 50DMA is 495.25 and the latest 200DMA is 402.90.

What are PANACEABIO PE, ROE and ROCE?

PANACEABIO has PE -626.02, ROE -0.65%, and ROCE -0.16% in Gimli's latest available snapshot.

How has PANACEABIO performed recently?

PANACEABIO has returned +2.32% over 1 month, +60.67% over 3 months, and +27.91% over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

PeriodRevenueEBITDAPATEPS
2026-03-31166.75 cr7.83 cr0.52 cr0.08
2025-12-31165.19 cr16.79 cr3.98 cr0.65
2025-09-30141.13 cr-8.69 cr-13.92 cr-2.27
2025-06-30166.70 cr15.81 cr4.05 cr0.66
2025-03-31132.53 cr9.42 cr-1.89 cr-0.31
2024-12-31163.49 cr14.35 cr4.52 cr0.74
2024-09-30147.35 cr14.42 crn/a0.77
2024-06-30115.72 cr-7.45 cr-15.80 cr-2.59

Annual income statement

YearRevenueEBITDAPATEPS
2026-03-31639.77 cr31.74 cr-5.37 crnan
2025-03-31559.09 cr30.74 cr-8.37 cr-1.37
2024-03-31551.93 cr40.86 cr-1.17 cr-0.19
2023-03-31456.92 cr55.73 cr-33.24 cr-5.43
2022-03-31248.07 cr1,672.97 cr-93.58 cr176.05

Balance sheet

PeriodAssetsCashDebtEquity
2026-03-311,262.17 cr57.31 cr23.66 cr828.88 cr
2025-03-311,289.75 cr82.12 cr15.00 cr830.62 cr
2024-03-311,240.82 cr47.17 cr15.00 cr838.23 cr
2023-03-311,271.17 cr39.85 cr20.22 cr840.11 cr
2022-03-311,758.87 cr50.35 cr0.05 cr873.65 cr

Cash flow

PeriodOCFFCFCash change
2026-03-3116.68 cr-37.41 crn/a
2025-03-31-27.37 cr-77.68 crn/a
2024-03-313.47 cr-79.41 crn/a
2023-03-31-422.45 cr-463.40 crn/a
2022-03-31-108.45 cr-120.96 crn/a

Shareholding Trend

PeriodPromoterFII/FPIDIIMFRetailPledge
2026-03-31+72.48%+1.60%+1.97%+0.00%+23.96%+0.00%
2025-12-31+72.48%+1.36%+1.85%+0.00%+24.30%+0.00%
2025-09-30+72.48%+1.06%+1.81%+0.00%+24.66%+0.00%
2025-06-30+72.48%+0.78%+1.52%+0.00%+25.22%+0.00%
2025-03-31+72.48%+1.16%+1.49%+0.00%+24.86%+0.00%
2024-12-31+72.49%+0.38%+1.17%+0.00%+25.97%+0.00%
2024-09-30+72.87%+0.37%+1.16%+0.00%+25.60%+0.00%
2024-06-30+73.46%+0.27%+1.07%+0.00%+25.20%+0.00%
2024-03-31+73.59%+0.27%+0.84%+0.00%+25.30%+0.00%
2023-12-31+73.59%+0.26%+0.69%+0.00%+25.46%+0.00%
2023-09-30+73.59%+0.26%+0.57%+0.00%+25.58%+0.00%
2023-06-30+73.59%+0.22%+0.54%+0.00%+25.66%+0.00%
2023-03-31+73.59%+0.18%+0.43%+0.00%+25.80%+0.00%
2022-12-31+73.59%+0.18%+0.43%+0.00%+25.80%+0.00%
2022-09-30+73.59%+0.14%+0.29%+0.00%+25.98%+0.00%
2022-06-30+73.59%+0.00%+0.00%n/an/a+0.00%
2022-03-31+73.59%+0.00%+0.00%n/an/a+0.00%
2021-12-31+73.59%+0.00%+0.13%n/an/a+94.27%
2021-09-30+73.59%+0.00%+0.42%n/an/a+94.27%
2021-06-30+73.59%+0.00%+0.45%n/an/a+94.27%

Industry Peers

SymbolNameMcapPEROE1Y
SUNPHARMASUN PHARMACEUTICAL IND L469,405.90 cr40.823336+14.71%+15.52%
DIVISLABDIVI S LABORATORIES LTD194,269.92 cr75.650281+16.19%+8.71%
TORNTPHARMTORRENT PHARMACEUTICALS L169,405.46 cr78.319677+17.18%+42.14%
APOLLOHOSPAPOLLO HOSPITALS ENTER. L128,040.28 cr65.380043+21.03%+21.93%
CIPLACIPLA LTD116,452.52 cr30.005339+11.79%-2.75%
ZYDUSLIFEZYDUS LIFESCIENCES LTD115,616.29 cr23.056854+17.93%+17.85%
LUPINLUPIN LIMITED113,320.96 cr21.221472+26.83%+28.27%
MAXHEALTHMAX HEALTHCARE INS LTD107,290.40 cr74.382732+14.33%-9.32%

Try these prompts

Related screen ideas

Data snapshot: 2026-07-20. Not investment advice.